Dirk De Ruysscher1, Kobe Reynders, Evert Van Limbergen, Maarten Lambrecht. 1. aMaastricht University Medical Center, Department of Radiation Oncology (Maastro Clinic), GROW School, Maastricht, The Netherlands bKU Leuven, Radiation Oncology cUniversity Hospitals Leuven, Department of Radiation Oncology/KU Leuven, Radiation Oncology, Leuven, Belgium.
Abstract
PURPOSE OF REVIEW: The immunomodulatory effects of ionizing radiation have long been recognized; however, so far these have not been fully exploited in clinical practice. We review the rationale to combine radiation with immune checkpoint inhibitors, which are used in standard practice. RECENT FINDINGS: Preclinical research suggests a synergy between radiotherapy and these immune checkpoint inhibitors. Whether or not this benefit translates into a clinical benefit is currently subject of ongoing research. SUMMARY: It is highly rational to combine radiation with immune therapy as in preclinical models and in proof of concept trials in humans it clearly can increase the antitumor immunity when given together with other immune interventions.
PURPOSE OF REVIEW: The immunomodulatory effects of ionizing radiation have long been recognized; however, so far these have not been fully exploited in clinical practice. We review the rationale to combine radiation with immune checkpoint inhibitors, which are used in standard practice. RECENT FINDINGS: Preclinical research suggests a synergy between radiotherapy and these immune checkpoint inhibitors. Whether or not this benefit translates into a clinical benefit is currently subject of ongoing research. SUMMARY: It is highly rational to combine radiation with immune therapy as in preclinical models and in proof of concept trials in humans it clearly can increase the antitumor immunity when given together with other immune interventions.
Authors: Farastuk Bozorgmehr; Adriane Hommertgen; Johannes Krisam; Felix Lasitschka; Jonas Kuon; Martin Maenz; Peter E Huber; Laila König; Meinhard Kieser; Juergen Debus; Michael Thomas; Stefan Rieken Journal: BMC Cancer Date: 2019-11-08 Impact factor: 4.430
Authors: Farastuk Bozorgmehr; Petros Christopoulos; Inn Chung; Jelena Cvetkovic; Manuel Feißt; Johannes Krisam; Marc A Schneider; Claus Peter Heußel; Michael Kreuter; Daniel W Müller; Michael Thomas; Stefan Rieken Journal: BMC Cancer Date: 2022-09-24 Impact factor: 4.638